---
document_datetime: 2023-09-21 22:16:13
document_pages: 12
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/iressa-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: iressa-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 21.7073027
conversion_datetime: 2025-12-20 01:18:35.656147
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Iressa

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued² / amended on   | Product Information affected3   | Summary   |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|--------------------------------------------|---------------------------------|-----------|
| IAIN/0039/G          | Thiswas an applicationfor a groupofvariations. A.5.a-Administrativechange-Changein thename and/oraddressof amanufacturer/importer responsibleforbatchrelease A.5.b-Administrativechange-Changeinthename | 14/07/2023                          |                                            | Annex II and PL                 |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedfor all otherprocedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

2A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g.summary of product characteristics,annex II, labelling,package leaflet).The CD is issued within twomonths of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation(EU) No.712/2012, or within one year for other procedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | and/or address of a manufacturer/importer of the finished product,including quality control sites (excludingmanufacturerforbatchrelease)                                                                                                                                                                                                                                                                         |            |            |                                  |                                |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------|
| IA/0038            | A.7-Administrativechange-Deletionof manufacturingsites                                                                                                                                                                                                                                                                                                                                                           | 18/07/2022 | n/a        |                                  |                                |
| IA/0037            | A.6-Administrative change-Change in ATC Code/ATCVetCode                                                                                                                                                                                                                                                                                                                                                          | 04/07/2022 |            | SmPC and PL                      |                                |
| PSUSA/1518/ 202107 | PeriodicSafetyUpdateEUSingleassessment- gefitinib                                                                                                                                                                                                                                                                                                                                                                | 10/02/2022 | n/a        |                                  | PRACRecommendation-maintenance |
| I1/0034            | Updateofsection4.8of theSmPCinordertoadd Palmar-plantarerythrodysaesthesiasyndrometothe listofadversedrugreactions(ADRs)withfrequency uncommon;thePackageLeafletisupdated accordingly.In addition,the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.1. C.I.4 -Change(s) in the SPC, Labelling or PL due to new quality,preclinical, clinical orpharmacovigilance data | 14/01/2021 | 04/02/2022 | SmPC, Annex II, Labelling and PL |                                |
| IB/0035            | B.I.a.1.z-Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS-Other variation                                                                                                                                                                                                                                                                                                    | 17/12/2020 | n/a        |                                  |                                |
| I1/0033            | C.I.11.b-Introduction of, or change(s) to, the obligations and conditions of a marketing                                                                                                                                                                                                                                                                                                                         | 03/09/2020 | n/a        |                                  |                                |

<div style=\"page-break-after: always\"></div>

|                    | authorisation,includingtheRMP-Implementationof change(s)whichrequire tobefurthersubstantiated bynewadditional data tobesubmittedby theMAH where significant assessment isrequired                                                                                                                                                                                                                         |            |            |                        |                                |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------|
| IAIN/0032/G        | This was an application for a group of variations. A.7-Administrativechange-Deletionof manufacturing sites B.II.b.2.c.2-Change to importer,batch release arrangements andqualitycontrol testingof theFp- Includingbatchcontrol/testing B.11.b.2.a-Change to importer,batch release arrangements and quality control testing of the FP - Replacement/additionofasitewherebatch control/testing takes place | 27/03/2019 | 09/03/2020 | Annex II and PL        |                                |
| PSUSA/1518/ 201807 | PeriodicSafetyUpdateEUSingle assessment - gefitinib                                                                                                                                                                                                                                                                                                                                                       | 14/02/2019 | n/a        |                        | PRACRecommendation-maintenance |
| IA/0030            | B.I.b.1.b-Change in the specification parameters and/or limits of anAS,starting material/intermediate/reagent-Tighteningof specification limits                                                                                                                                                                                                                                                           | 27/07/2018 | n/a        |                        |                                |
| IB/0029            | C.I.z - Changes (Safety/Efficacy) of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                                                                 | 23/04/2018 | 08/04/2019 | SmPC, Labelling and PL |                                |
| IA/0028            | A.4-Administrativechange-Changein thename and/or address of a manufacturer or an ASMF holder orsupplieroftheAS,startingmaterial,reagentor                                                                                                                                                                                                                                                                 | 23/06/2017 | n/a        |                        |                                |

<div style=\"page-break-after: always\"></div>

|         | intermediateusedinthemanufactureoftheASor manufacturerof a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0026 | Updateof section4.1of theSmPCin order tospecify thatIressashouldbeused asmonotherapy andnot in combination withothermedicines in its approved indicationbasedon thesubmissionofthefinalstudy report of the IMPRESS (D791LC00001) study following thePRACrecommendationinconclusion to theassessmentofthe8thPSUR.TheRMPwas updated in consequence in order to addas identified riskthecontinuationofgefitinibasadd-onto chemotherapyinpatientswithsecondaryresistance to gefitinib (agreed version 10.0). C.I.13-Other variations notspecifically covered elsewhereinthisAnnexwhichinvolvethesubmission | 23/02/2017 | 29/03/2017 | SmPC |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| II/0027 | Updateofsection5.1oftheSmPCinorder toupdate informationonmechanismsofresistance togefitinib inpatientswithEGFRmutationpositiveNon-Small CellLung Cancer(NSCLC)as proposed during assessment of LEG 21. In addition, the Marketing authorisationholder(MAH)tookthe opportunity to introducesomeeditorialchangesintheSmPC C.I.3.b -Change(s) in the SPC,Labelling or PL intended toimplementtheoutcomeofaprocedure concerningPSURorPASSor theoutcomeofthe assessment done underA 45/46-Change(s)with                                                                                                     | 26/01/2017 | 29/03/2017 | SmPC | MostNSCLC tumourswithsensitisingEGFRkinase mutationseventuallydevelopresistancetoIRESSA treatment,with amedian time todiseaseprogressionof1 year.Inabout60%of cases,resistance is associatedwith a secondaryT790MmutationforwhichT790MtargetedEGFR TKIsmaybe considered as a next line treatment option. Otherpotentialmechanismsofresistancethathavebeen reported following treatment with EGFR signal blocking agents include: bypass signalling such as HER2 and MET gene amplificationandPIK3CAmutations.Phenotypic switchtosmallcell lungcancerhasalsobeenreportedin5- 10%of cases. |

<div style=\"page-break-after: always\"></div>

|                    | new additional datasubmittedbytheMAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |                        |                                |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------|
| I1/0025            | Updateofsection4.8of theSmPCinordertoupdate the safety information on allergic reaction amending the frequency from Uncommon to Common.The PackageLeaflet is updated accordingly.In addition, the Marketing authorisationholder(MAH) took the opportunity to align the Package leaflet with the SmPCaddingdrymouthas acommonsideeffects in section4.TheMAH tookalsotheopportunity to introduceminor editorial changes,toupdate the list of localrepresentativesforPolandinthePackage Leafletand tobring thePIinlinewiththelatestQRD templateversion 10.0. C.I.4 -Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 15/09/2016 | 29/03/2017 | SmPC, Labelling and PL |                                |
| II/0024            | Updateofsection5.3of theSmPCinordertoupdate information thattheclinicalexperiencehasnot shownacausalassociationbetweenQTprolongation and gefitinib. C.I.4 -Change(s) in the SPC, Labelling or PL due to new quality,preclinical, clinical orpharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                         | 15/09/2016 | 29/03/2017 | SmPC                   |                                |
| PSUSA/1518/ 201507 | Periodic Safety Update EU Single assessment - gefitinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 14/01/2016 | n/a        |                        | PRACRecommendation-maintenance |

<div style=\"page-break-after: always\"></div>

| IA/0022            | B.II.d.2.e-Change in test procedure for the finished product-Update of the testprocedureto comply with the updated general monograph in thePh.Eur.                                                         | 08/01/2016   | n/a        |            |                                                                                                                                                                                                                               |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0633            | C.I.8.a-Introduction of orchanges to a summary of Pharmacovigilancesystem-ChangesinQPPV (including contact details) and/or changes in the PSMF location                                                    | 09/12/2015   | n/a        |            |                                                                                                                                                                                                                               |
| IA/0021            | A.4-Administrativechange-Changeinthename and/oraddressofamanufactureroranASMFholder orsupplieroftheAS，startingmaterial,reagentor intermediateused inthemanufactureof theASor manufacturerofanovelexcipient | 02/12/2015   | n/a        |            |                                                                                                                                                                                                                               |
| PSUSA/1518/ 201407 | PeriodicSafetyUpdateEUSingle assessment- gefitinib                                                                                                                                                         | 12/02/2015   | n/a        |            | PRACRecommendation-maintenance                                                                                                                                                                                                |
| IA/0018            | A.5.b-Administrative change -Change in the name and/or addressof amanufacturer/importerof the finishedproduct,including qualitycontrol sites (excludingmanufacturerforbatchrelease)                        | 23/12/2014   | n/a        |            |                                                                                                                                                                                                                               |
| 11/0016            | C.I.4 -Change(s)in the SPC, Labelling or PL due to newquality,preclinical,clinicalorpharmacovigilance data                                                                                                 | 25/09/2014   | 15/10/2015 | SmPC       |                                                                                                                                                                                                                               |
| R/0012             | Renewalofthemarketing authorisation.                                                                                                                                                                       | 20/02/2014   | 23/04/2014 | SmPC andPL | The CHMP, having reviewed the available information on thestatusofthefulfilmentofpost-authorisationmeasures andhaving confirmedthepositivebenefit/riskbalance,is of the opinion that the quality, safety and efficacy of this |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |     | medicinal productcontinue tobe adequately and sufficientlydemonstratedand thereforerecommendsthe renewal of Iressa,subject to the Conditions as laid down in AnnexIItotheOpinion.TheCHMPrecommendsthatthe renewal be granted with unlimited validity.   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0014/G | This was an applicationfor a group of variations. B.II.b.1.e-Replacementoradditionofa manufacturing sitefor theFP-Sitewhere any manufacturing operation(s)takeplace,exceptbatch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.2.a -Change to importer,batch release arrangements and quality control testing of the FP - Replacement/additionofasitewherebatch control/testingtakesplace B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change inthemanufacturingprocess B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size | 28/02/2014 | n/a |                                                                                                                                                                                                                                                         |
| IG/0402   | C.I.8.a-Introductionofor changesto a summary of Pharmacovigilancesystem-ChangesinQPPV (including contact details) and/or changesin the PSMF location                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 27/02/2014 | n/a |                                                                                                                                                                                                                                                         |
| PSUV/0013 | PeriodicSafetyUpdate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 06/02/2014 | n/a | PRACRecommendation-maintenance                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| 11/0011   | Updateofsection5.1oftheSmPCinordertoreflect the results of study D791AC00014 (IFUM). In addition,theMAH tookthe opportunity to update thelistoflocalrepresentativesinthePackage Leaflet. Furthermore, the PI is being brought in line with thelatestQRDtemplateversion9.0. C.I.4 -Variations related to significant modifications of theSPCdueinparticular tonewquality,pre- clinical, clinical or pharmacovigilance data   | 27/06/2013   | 23/04/2014   | SmPC, Annex II and PL            | Thisvariationreflects theresultsfrom theIRESSAFollow- Up Measure (IFUM) study (D791AC00014) on the efficacy andsafetyofgefitinib(250mgorallyoncedaily)asfirst- line treatment in Caucasian patients with activating sensitising EGFRmutation-positive(EGFRM+）locally advanced ormetastaticNSCLC.Results of this study are consistent with the results from the pivotal trial conducted inAsianpatientswhich isreflected insection5.1of the SmPC.   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0273   | C.I.z-Changes(Safety/Efficacy)ofHumanand VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                                                                                         | 08/02/2013   | n/a          |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IB/0009/G | This was an application for a group of variations. B.I.a.1.z-Change in the manufacturer of ASor of a startingmaterial/reagent/intermediateforAS-Other variation B.I.a.1.z-Change in the manufacturer ofAS or of a startingmaterial/reagent/intermediateforAS-Other variation B.I.c.1.a-Change in immediate packaging of the AS -Qualitativeand/orquantitativecomposition                                                    | 30/11/2012   | n/a          |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IA/0008   | A.7-Administrativechange-Deletion of manufacturingsites                                                                                                                                                                                                                                                                                                                                                                     | 31/07/2012   | n/a          |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| I1/0005   | Updateof sections4.4and4.8oftheSmPCinorder toaddawarningonthedevelopmentofkeratitis and ulcerativekeratitis.ThePackageLeafletwas updated                                                                                                                                                                                                                                                                                    | 15/03/2012   | 20/04/2012   | SmPC, Annex II, Labelling and PL | ThePhvwP,havingreviewedreportsofkeratitis and ulcerativekeratitis acrossEGFRinhibitorsclassofproducts, recommended a warning in the SmPC, which was endorsed                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|           | accordingly.In addition,the MAH took the opportunity to update the list of local representatives inthePackageLeaflet.Furthermore,theProduct Information wasbrought inlinewiththelatestQRD templateversion8. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR,RMP,FUM/SO,data submittedunderArticle 45/46,or amendments toreflect aCoreSPC- Change(s)with new additional data submitted by the MAH   |            |            |             | bytheCHMP.FollowingarequestfromtheCHMP,theMAH submitted avariation to add the warning of keratitis and ulcerativekeratitis andprovided additional analysesfrom theFDA'ssafetydatabase,theWHOVigibaseand the MAH'sworldwidesafetydatabase.TheMAHreported13 eventsofkeratitisand1eventofulcerativekeratitiswith the use ofgefitinib.The product informationhasbeen amendedwithawarninginsection4.4 and4.8of the SmPC.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0124/G | This was an application for a group of variations. C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-upprocedureoftheQPPV C.I.9.h-Changes to anexistingpharmacovigilance system as described in the DDPS - Other change(s) totheDDPSthatdoesnotimpactontheoperationof the pharmacovigilance system                                                                                                       | 18/11/2011 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                       |
| I1/0004   | In this variation the MAH has updated the section5.1 oftheSmPCbasedonupdatedoverallsurvival(OS) datafromtheIPASSstudyfurthertotherequestof the CHMPfollowing the assessmentofFUM 002.In addition to this, the MAH updated the section 5.1 of theSmPCwiththeefficacyoutcomesoftheEGFR mutation-unknown subgroup ofpatientsfrom this study.                                                                                                                      | 23/06/2011 | 01/08/2011 | SmPC and PL | Section5.1of theSmPChasbeenupdatedwith a new analysisofoverall survival(OS)datafromtheIPASS Study.IntheIPASStrial,IRESSA demonstratedsuperior PFS,ORR,QoL andsymptomreliefwithnosignificant differenceinOScomparedtocarboplatin/paclitaxel in previously untreated patients, with locally advanced or metastaticNSCLC,whose tumoursharboured activating mutations of theEGFRtyrosinekinase.                           |

<div style=\"page-break-after: always\"></div>

|           | TheMAH alsotooktheopportunity toupdatethelist of thelocalrepresentatives in thePackageLeaflet.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0035   | C.I.9.i-Changes to an existingpharmacovigilance system as described in the DDPS - Change(s) to a DDPSfollowing the assessmentofthesameDDPSin relationtoanothermedicinalproductofthesame MAH                                                                                                                                                                                                                                                                                                                                                                                                                                             | 07/01/2011 | n/a        | Annex II                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| I1/0003/G | This was an applicationfor a group of variations. This was an applicationfor a group of variations. Updateofsection4.8oftheSummaryofProduct Characteristics(SmPC)toupdate thefrequency of hepatitis and toaddthe adversereactions gastrointestinal perforation, skin fissures, bullous conditions, cutaneous vasculitis, cystitis and haemorrhagiccystitisfurthertosafetyreviews conductedbytheMarketingAuthorisationHolder (MAH).Section4.4oftheSmPCwasalsoupdatedto reflecttheinformationrelativetohepatitis and gastrointestinal perforation. The Package Leaflet was amendedaccordingly. TheMAHalsoupdatedsection4.9\"overdose\"ofthe | 21/10/2010 | 26/11/2010 | SmPC,Annex II, Labelling and PL | TheProductinformation ofIressa isupdatedwithrecent safety informationobtainedfrom clinical trials andpost marketing surveillance. Basedonfivereportsof hepatitisidentifiedinclinical trials, thefrequencyofhepatitishasbeenrevisedtouncommon adversereaction.AnalysisoftheMAHsafetydatabase also showedthatfewreports,all containingconfoundingfactors, resulted inhepaticfailure associated insome caseswith a fatal outcome.Therefore, this information has been included in the existing warningrelated tohepatitis. Gastro-intestinal(GI)perforationhasbeen observed in clinicalstudiesandpost-marketingsurveillance.Basedon5 reportsof GIperforation observed inclinicaltrials,the frequencyhasbeendefined asuncommon.Theoverall safetyresults showed thatuse ofIressa is arelevantco- |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | TheEURMPhasbeenrevised accordingly and its version number(version 6)hasbeen updated in Annex II. In addition,details of theblister and aluminium laminatefoilflow-wraphavebeencombinedunder AnnexIIIAandminorchangesweremadeto thelist ofrepresentativesinAnnexIIIB. Lastly,minoreditorial changes and updatesbased on the latest QRD template(version 7.3.1.)were made through the product information. C.I.4-Variationsrelatedtosignificantmodifications of theSPCdue inparticular tonewquality,pre- clinical,clinical or pharmacovigilancedata C.I.4 -Variations related to significant modifications of theSPCdue inparticular to newquality,pre-   |            |            |          | Basedon the results of the safety reviews,cystitis and haemorrhagiccystitishavebeenincluded insection4.8of the SmPC with the frequency of \"common\" and \"rare\" respectively. Inrelationtoskinreactions,areviewofthesafetydata indicated thatskinfissures,bullous conditions and cutaneousvasculitishavebeen observed.Therefore,these adversereactionshavebeen added totheSmPC. Lastly,safetydatafrom aphaseIdoseescalationstudy evaluatinghighdoseofIressa（1,500to3,500mg)have shownconsistentresultswiththeestablishedsafetyprofile ofIressa,whichwasgenerally well tolerated,with no unexpectedsafety ortolerabilityconcernsidentified.The overdosesection4.9oftheSmPChasbeenupdated accordingly.   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0002 | UpdateoftheDetailedDescriptionof PharmacovigilanceSystem(DDPS).Consequently, AnnexIIhasbeenrevisedwiththenewversion number of the agreed DDPS(version10).Minor updateswereimplementedintheRiskManagement Plan. UpdateofSummaryofProductCharacteristics                                                                                                                                                                                                                                                                                                                                                                                                  | 17/12/2009 | 19/01/2010 | Annex II | TheDetailedDescriptionofPharmacovigilanceSystem (DDPS)was updated andconsequently,AnnexIIhasbeen revisedwiththenewversionnumberoftheagreedDDPS (version10).Minorupdates were implemented in the Risk ManagementPlan.The CHMP considers that the Pharmacovigilancesystemasdescribedbytheapplicant fulfilstherequirements andprovidesadequateevidence thattheapplicanthastheservicesofaqualifiedperson responsibleforPharmacovigilance andhasthenecessary meansforthenotification of any adversereaction suspectedofoccurringeitherintheCommunityorinathird country.                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| IA/0001   | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size   | 17/09/2009   | 17/09/2009   | SmPC, Labelling and PL   |
|-----------|-------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|